No, Lexiscan (regadenoson) is NOT a functional assessment—it is an anatomical/perfusion assessment tool
Lexiscan is a pharmacological vasodilator stress agent that evaluates myocardial perfusion by detecting relative differences in blood flow between normal and stenotic coronary territories, not the functional consequences of ischemia on myocardial contractility or oxygen demand-supply mismatch. This is a critical distinction in cardiovascular stress testing 1, 2.
Understanding the Distinction
What Lexiscan Actually Does
Regadenoson works as a selective A2A adenosine receptor agonist that causes coronary vasodilation in normal epicardial arteries 2. The mechanism is fundamentally different from functional stress:
- Vasodilators reduce myocardial oxygen supply through horizontal steal (in presence of coronary collaterals) and vertical steal (with critical stenosis) 1
- They reveal the anatomical limitation of flow in stenotic vessels that cannot vasodilate as much as normal vessels 2
- This creates a relative perfusion defect visualized with nuclear tracers or contrast agents—not a functional wall motion abnormality
True Functional Assessment
In contrast, functional assessment involves:
- Exercise or dobutamine stress that increases myocardial oxygen demand by raising contractility, heart rate, and blood pressure 1, 2
- Detection of regional wall motion abnormalities (RWTA) or metabolic consequences of ischemia 3
- Assessment of the heart's ability to respond to physiologic stress
Clinical Implications
The 2024 ESC guidelines explicitly state that vasodilators like regadenoson are used for perfusion imaging, while dobutamine is preferred for viability and functional assessment 1. The 2013 AHA scientific statement clarifies that vasodilator stress "unmasks locally limited capacity for coronary vasodilatation" rather than assessing "metabolic or functional consequences of the mismatch between oxygen supply and demand" 2.
When to Use Regadenoson
Regadenoson is appropriate for:
- Myocardial perfusion imaging (SPECT or PET) in patients unable to exercise 2, 4, 2
- Patients with bronchospastic disease (safer than adenosine due to A2A selectivity) 5, 6
- Simplified workflow with fixed 0.4 mg bolus dose over 10 seconds 1
- Assessment of coronary flow reserve (CFVR) 1
Important Caveats
- Regadenoson does NOT assess contractile reserve or viability—use low-dose dobutamine for these indications 1
- In patients with left bundle branch block, pharmacological stress with vasodilators is preferred over exercise to avoid false-positive septal defects 5, 6
- The drug has prolonged hemodynamic effects: heart rate and ejection fraction changes persist 15+ minutes post-injection, so functional imaging sequences should be performed BEFORE vasodilator administration if needed 7
- Serious adverse events are rare but include STEMI (can occur 1-30 minutes post-injection), requiring continuous monitoring 8, 9
Bottom Line
Lexiscan reveals anatomical perfusion limitations through vasodilation, not functional ischemic consequences through increased demand. If you need functional assessment—particularly for viability, contractile reserve, or true exercise capacity—choose exercise or dobutamine stress with wall motion analysis instead 1, 3.